Details

Autor(en) / Beteiligte

• Martin-Broto, J.
• Gutierrez, A.
• Garcia-del-Muro, X.
• Lopez-Guerrero, J.A.
• Martinez-Trufero, J.
• de Sande, L.M.
• Lainez, N.
• Maurel, J.
• De Juan, A.
• Losa, F.
• Andres, R.
• Casado, A.
• Tejido, P.G.
• Blanco, R.
• Carles, J.
• Bellmunt, J.
• Gomez-España, A.
• Ramos, R.
• Martinez-Serra, J.
• Llombart-Bosch, A.
• Poveda, A.

Titel

Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study

Ist Teil von

• Annals of oncology, 2010-07, Vol.21 (7), p.1552-1557

Ort / Verlag

Oxford: Elsevier Ltd

Erscheinungsjahr

2010

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• To assess whether deletions involving codons 557 and/or 558 (critical deletions) of exon 11 of KIT are relevant in the prognosis of relapse-free survival (RFS) in gastrointestinal stromal tumor (GIST) patients with a long follow-up. A univariate and multivariate analysis for RFS were carried out on 162 localized GIST patients over the entire follow-up period and over the intervals 0–4 years and >4 years. Factors assessed among others were Fletcher/National Institutes of Health and Miettinen–Lasota/Armed Forces Institute of Pathology (M-L/AFIP) risk categories, critical deletions and non-deletion-type mutation (NDTM) within exon 11 of KIT. Multivariate analyses revealed that M-L/AFIP [relative risk (RR) 11.45, confidence interval (CI) 4.40–29.76, for the high-risk subgroup and RR 5.97, CI 2.09–17.06, for the intermediate subgroup] and critical deletions (RR 3.05, CI 1.59–5.85) were independent prognostic factors for RFS for the first 4 years and for the entire follow-up period. Beyond 4 years, the high-risk M-L/AFIP subgroup (RR 8.12, CI 1.48–44.4) and NDTM (RR 6.42, CI 1.17–35.12) were independent prognostic factors for RFS. The median follow-up was 84 months. Critical deletions represent a time-dependent prognostic factor limited to the first 4 years after surgery, which could help identify a subset with higher and earlier risk for relapse in GIST patients.